https://www.pleryon.com/news-1/pleryon-therapeutics-receives-approval-from-health-canada-to-undertake-a-first-in-human-clinical-trial-for-its-lubricin-inspired-polymer-p002-in-dry-eye-disease-at-core%2C-university-of-waterloo 2026-01-23 https://www.pleryon.com/news-1/pleryon-therapeutics-appoints-global-dry-eye-experts-prof.-lyndon-jones-and-prof.-fiona-stapleton-as-scientific-advisors 2025-10-11 https://www.pleryon.com/news-1/pleryon-therapeutics-completes-5m-series-a-financing-to-accelerate-clinical-development-of-innovative-therapies-for-osteoarthritis-and-dry-eye-disease 2025-10-11 https://www.pleryon.com/news-1/pleryon-therapeutics-joints-jlabs%40shanghai 2025-10-11 https://www.pleryon.com/news-1/pleryon-therapeutics-announces-global-exclusive-license-agreement-for-a-novel--therapeutic-polymer-for-the-treatment-of-osteoarthritis 2025-10-11 https://www.pleryon.com/news-1/pleryon-therapeutics-announced-securing-closed-to-100-million-rmb-in-a-pre-a-funding-round 2025-10-11 https://www.pleryon.com/news-1/seqens-partners-with-pleryon-to-develop-and-manufacture-an-innovative-gmp-polymer-to-treat-osteoarthritis 2025-10-11 https://www.pleryon.com/news-1/pleryon-therapeutics-received-gold-medal-with-congratulations-of-the-jury-at-the-48th-international-exhibition-of-inventions-geneva 2025-10-11